Journals / Turkish Journal of Gastroenterology / 2019 / Cilt: 30 - Sayı: 4

Upregulation of SIRT1 gene in gastric adenocarcinoma

Pages
326–330
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The SIRT1 gene was upregulated in all tumor stage subgroups except stage I, femalepatients, young patients (≤45 years), and corpus and cardia tumor subgroups compared to the control group.Conclusion: SIRT1 gene overexpression is associated with gastric adenocarcinoma, and it can be argued that SIRT1 gene upregulationis associated with unfavorable gastric adenocarcinoma prognosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: SIRT1 gene overexpression is reportedly associated with cancer development, via the triggering of DNA repair impairment, and cell proliferation.
📊
Key Findings & Data:The study aimed to investigate SIRT1 expression in patients with gastric cancer and its correlations withthe clinical and pathological characteristics of the disease.Materials and Methods: All patients (64 patients) who underwent gastric biopsy and were diagnosed with gastric adenocarcinoma andsignet ring cell carcinoma between January 2011 and December 2013 were enrolled in the study, and patients with benign gastric biopsywere enrolled in the control group (34 patients).
💡
Conclusion & Impact:The SIRT1 gene was upregulated in all tumor stage subgroups except stage I, femalepatients, young patients (≤45 years), and corpus and cardia tumor subgroups compared to the control group.Conclusion: SIRT1 gene overexpression is associated with gastric adenocarcinoma, and it can be argued that SIRT1 gene upregulationis associated with unfavorable gastric adenocarcinoma prognosis.
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Özet

Background/Aims: SIRT1 gene overexpression is reportedly associated with cancer development, via the triggering of DNA repair impairment, and cell proliferation. The study aimed to investigate SIRT1 expression in patients with gastric cancer and its correlations withthe clinical and pathological characteristics of the disease.Materials and Methods: All patients (64 patients) who underwent gastric biopsy and were diagnosed with gastric adenocarcinoma andsignet ring cell carcinoma between January 2011 and December 2013 were enrolled in the study, and patients with benign gastric biopsywere enrolled in the control group (34 patients). The previously prepared gastric tissues were collected from the pathology department,and SIRT1 gene expressions were evaluated in the gastric tissues of all study patients. Patients were subclassified according to theirdemographic, clinical, and pathologic features, and the patient and control groups were compared.Results: Sixty-four patients were included in the study (25 females and 39 males). The mean age of the patients was 66±1 (range: 33-88) years. The SIRT1 gene 2’ Average delta cycle threshold (CT) value was 0.102 in the control group, whereas it was 0.292 in the patientswith gastric cancer (relative risk: 2.86; p=0.014). The SIRT1 gene was upregulated in all tumor stage subgroups except stage I, femalepatients, young patients (≤45 years), and corpus and cardia tumor subgroups compared to the control group.Conclusion: SIRT1 gene overexpression is associated with gastric adenocarcinoma, and it can be argued that SIRT1 gene upregulationis associated with unfavorable gastric adenocarcinoma prognosis.

🔖

Cite This Article

ÖZCAN, Ö., BELLİ, A. K., ÇETİN, E. S., KARA, M., ÇELİK, Ö. İ., KAPLAN, M., KAYILIOĞLU, S. I., DÖNMEZ, C., POLAT, M. (2019). Upregulation of SIRT1 gene in gastric adenocarcinoma. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 4, 326–330. https://ajindex.com/articles/409294

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol 2009
  2. [CrossRef] Yuan H, Su L, Chen WY. The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther 2013
  3. Hiraike H, Wada-Hiraike O, Nakagawa S, et al. Expression of DBC1 is associated with nuclear grade and HER2 expression in breast cancer. Exp Ther Med 2011
  4. [CrossRef] Wang F, Chan CH, Chen K, et al. Deacetylation of FOXO3 by Sirt1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation. Oncogene 2012
  5. [CrossRef] Noh S J, Baek HA, Park HS, et al. Expression of Sirt1 and cortactin is associated with progression of non-small cell lung cancer. Pathol Res Pract 2013
  6. [CrossRef] Menssen A, Hydbring P, Kapelle K, et al. The c-MYC oncoprotein, the NAMPT enzyme, the Sirt1-inhibitor DBC-1, and the Sirt1 deacetylase form a positive feedback loop. Proc Natl Acad Sci U S A. 2012
  7. [CrossRef] Allison SJ, Jiang M, Milner J. Oncogenic viral protein HPV E7 up-regulates the Sirt1 longevity protein in human cervical cancer cells. Aging 2009
  8. [CrossRef] Marshall GM, Liu PY, Gherardi S, et al. Sirt1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet 2011
  9. e1002135. [CrossRef] Kozako T, Aikawa A, Shoji T, et al. High expression of the longevity gene product Sirt1 and apoptosis induction by sirtinol in adult T-cell leukemia cells. Int J Cancer 2012
  10. [CrossRef] Dickson BC, Riddle ND, Brooks JS, et al. “Sirtuin 1 (Sirt1): a potential immunohistochemical marker and therapeutic target in soft tissue neoplasms with myoid differentiation.” Human Pathol 2013
  11. [CrossRef] Ries LAG, Reichman ME, Lewis DR, et al. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003
  12. [CrossRef] McLean MH, El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol 2014
  13. [CrossRef] Kang Y, Jung WY, Lee H, et al. Expression of Sirt1 and DBC1 in Gastric Adenocarcinoma. Korean J Pathol 2012
  14. [CrossRef] Vaziri H, Dessain SK, Eaton EN, et al. hSIR2(Sirt1) functions as an NAD-dependent p53 deacetylase. Cell 2001
  15. [CrossRef] Somasundaram K, El-Deiry WS. Tumor suppressor p53: regulation and function. Front Biosci 2000
  16. [CrossRef] Firestein R, Blander G, Michan S, et al.